Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • drlongandstrong drlongandstrong Sep 12, 2013 12:23 PM Flag

    Leerink says AMRN weakness a buying op. Read here...

    Leerink recommends investors use today's weakness in shares of Amarin as a buying opportunity. The firm does not believe Amarin's Vascepa and Lovaza, which may face generic competition in the second half of 2013 after today's court ruling, will compete on price. Leerink says Vascepa remains best in class and keeps an Outperform rating on shares of Amarin.

    Sentiment: Strong Buy

 
AMRN
1.94+0.110(+6.01%)May 2 4:00 PMEDT